These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 31451998)

  • 21. The validity of melatonin as an oncostatic agent.
    Panzer A; Viljoen M
    J Pineal Res; 1997 May; 22(4):184-202. PubMed ID: 9247204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial.
    Lissoni P; Chilelli M; Villa S; Cerizza L; Tancini G
    J Pineal Res; 2003 Aug; 35(1):12-5. PubMed ID: 12823608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular tools to study melatonin pathways and actions.
    Boutin JA; Audinot V; Ferry G; Delagrange P
    Trends Pharmacol Sci; 2005 Aug; 26(8):412-9. PubMed ID: 15992934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New insights into antimetastatic signaling pathways of melatonin in skeletomuscular sarcoma of childhood and adolescence.
    Lu KH; Lin CW; Hsieh YH; Su SC; Reiter RJ; Yang SF
    Cancer Metastasis Rev; 2020 Mar; 39(1):303-320. PubMed ID: 32086631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization and biological activities of melatonin in intact and diseased gastrointestinal tract (GIT).
    Konturek SJ; Konturek PC; Brzozowska I; Pawlik M; Sliwowski Z; Cześnikiewicz-Guzik M; Kwiecień S; Brzozowski T; Bubenik GA; Pawlik WW
    J Physiol Pharmacol; 2007 Sep; 58(3):381-405. PubMed ID: 17928638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Participation of MT3 melatonin receptors in the synergistic effect of melatonin on cytotoxic and apoptotic actions evoked by chemotherapeutics.
    Pariente R; Bejarano I; Espino J; Rodríguez AB; Pariente JA
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):985-998. PubMed ID: 28956121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The regulatory role of melatonin in skeletal muscle.
    Chen B; You W; Shan T
    J Muscle Res Cell Motil; 2020 Sep; 41(2-3):191-198. PubMed ID: 32157560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melatonin: Nature's most versatile biological signal?
    Pandi-Perumal SR; Srinivasan V; Maestroni GJ; Cardinali DP; Poeggeler B; Hardeland R
    FEBS J; 2006 Jul; 273(13):2813-38. PubMed ID: 16817850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Melatonin: what for?].
    Touitou Y
    Bull Acad Natl Med; 2005 May; 189(5):879-89; discussion 889-91. PubMed ID: 16433460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo.
    Winczyk K; Pawlikowski M; Lawnicka H; Kunert-Radek J; Spadoni G; Tarzia G; Karasek M
    Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():50-4. PubMed ID: 12019352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin: a pleiotropic molecule regulating inflammation.
    Radogna F; Diederich M; Ghibelli L
    Biochem Pharmacol; 2010 Dec; 80(12):1844-52. PubMed ID: 20696138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melatonin: pharmacological aspects and clinical trends.
    Rios ER; Venâncio ET; Rocha NF; Woods DJ; Vasconcelos S; Macedo D; Sousa FC; Fonteles MM
    Int J Neurosci; 2010 Sep; 120(9):583-90. PubMed ID: 20707632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential role of melatonin in prevention and treatment of leukaemia.
    Ng MG; Ng KY; Koh RY; Chye SM
    Horm Mol Biol Clin Investig; 2021 Aug; 42(4):445-461. PubMed ID: 34355548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines.
    Sánchez-Hidalgo M; Lee M; de la Lastra CA; Guerrero JM; Packham G
    J Pineal Res; 2012 Nov; 53(4):366-73. PubMed ID: 22582944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of melatonin treatment in primary culture of canine mammary tumors.
    Lopes JR; Maschio LB; Jardim-Perassi BV; Moschetta MG; Ferreira LC; Martins GR; Gelaleti GB; De Campos Zuccari DA
    Oncol Rep; 2015 Jan; 33(1):311-9. PubMed ID: 25384569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin: a potential intervention for hepatic steatosis.
    Sun H; Huang FF; Qu S
    Lipids Health Dis; 2015 Jul; 14():75. PubMed ID: 26199093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Understanding the oncostatic actions displayed by melatonin in colorectal cancer therapy.
    Gil-Martín E; López-Muñoz F; Reiter RJ; Romero A
    Future Med Chem; 2020 Jul; 12(13):1201-1204. PubMed ID: 32466682
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic targets of cancer drugs: Modulation by melatonin.
    Moloudizargari M; Moradkhani F; Hekmatirad S; Fallah M; Asghari MH; Reiter RJ
    Life Sci; 2021 Feb; 267():118934. PubMed ID: 33385405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin in cancer management: progress and promise.
    Jung B; Ahmad N
    Cancer Res; 2006 Oct; 66(20):9789-93. PubMed ID: 17047036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circadian stage-dependent inhibition of human breast cancer metabolism and growth by the nocturnal melatonin signal: consequences of its disruption by light at night in rats and women.
    Blask DE; Dauchy RT; Brainard GC; Hanifin JP
    Integr Cancer Ther; 2009 Dec; 8(4):347-53. PubMed ID: 20042410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.